Solid Biosciences licenses AAV-SLB101 to Andelyn Biosciences for gene therapy development.
ByAinvest
Monday, Nov 17, 2025 8:03 am ET1min read
SLDB--
Solid Biosciences has announced a non-exclusive license and collaboration agreement with Andelyn Biosciences for its proprietary AAV-SLB101 capsid. The agreement will allow Andelyn to use AAV-SLB101 for its cell and gene therapy products. AAV-SLB101 has been well-tolerated in a Phase 1/2 clinical trial with 23 participants. Solid continues to expand its collaborative efforts for AAV-SLB101 with over 30 agreements.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet